Trial Profile
A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Corticosteroids; Sirolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 06 Aug 2012 New trial record